eMedicine Specialties > Pediatrics: General Medicine > Rheumatology

Neonatal Lupus and Cutaneous Lupus Erythematosus in Children

Jeffrey P Callen, MD, Professor of Medicine, Chief, Division of Dermatology, University of Louisville School of Medicine

Updated: Jul 20, 2009

Introduction

Background

Lupus erythematosus (LE) is a rare condition in children. Most cases take the form of systemic lupus erythematosus (SLE). This article discusses cutaneous lesions of lupus in neonates and children, as well as the relationship of these lesions to systemic disease. Specifically, this article addresses (1) neonatal LE (NLE), which usually manifests as nonscarring, non–atrophy-producing lesions known as subacute cutaneous LE (SCLE), and (2) cutaneous lesions of lupus erythematosus in children and adolescents.

Neonatal lupus erythematosus.

Pathophysiology

Neonatal lupus erythematosus is thought to be related to circulating maternal autoantibodies; however, most infants exposed to these antibodies in utero do not develop disease. In one study, serum immunoglobulin G (IgG) from the mother of a neonate with congenital heart block (CHB) inhibited L-type calcium channels in a rat heart model.¹ Additionally, induction of apoptosis in cultured cardiocytes has been demonstrated to result in the expression of Ro/La antigens on the cell surface. However, the antibodies associated with heart block and with cutaneous disease are believed to be different, with the Ro (SS-A) against the 52/60-kd protein associated with heart block, and the La (SS-B) against the 50-kd protein associated with cutaneous disease.

However, only some neonates exposed to these antibodies develop complications; therefore, other factors must be involved. These may include genetic predisposition, viral infection, and other unknown factors. The risk of neonatal lupus erythematosus or CHB developing in a woman who tests positive for Ro/SS-A who has never had a child with neonatal lupus erythematosus or CHB is less than 1%, whereas the risk for a mother who has had an affected infant is roughly 25%.

Neonatal lupus erythematosus may affect the skin, heart, liver, blood-forming elements, CNS, or the spleen.

Frequency

United States

Neonatal lupus erythematosus occurs in 1 of every 20,000 live births. Lupus erythematosus of childhood occurs in 0.6 of every 100,000 children annually.

Mortality/Morbidity

Neonatal lupus erythematosus has significant associated morbidity and mortality when the heart is affected. In patients with cardiac involvement, neonatal lupus erythematosus may manifest as complete or incomplete CHB. Heart block is evident in utero or at birth. In children who are severely affected, a pacemaker is frequently needed because sudden death or heart failure may occur. However, many children with CHB may be relatively asymptomatic until adolescence, when they begin to exercise. At this time, they may develop syncope and require a pacemaker implantation.

Most patients with neonatal lupus erythematosus of the skin, liver, or blood have transient disease that spontaneously resolves within 4-6 months. Children rarely develop systemic lupus erythematosus later in life. Siblings of affected individuals also have a risk of developing systemic lupus erythematosus later in life.

Morbidity and mortality of systemic lupus erythematosus of childhood depend on the organ systems affected. If the kidneys are affected, renal failure may occur. Joint disease does not lead to deformity but may be debilitating. Disease of the skin may lead to scar formation; however, in isolation, it is associated with a good prognosis.

Race

No racial predilection has been observed. However, lupus erythematosus of childhood appears to be more common in African Americans, Latin Americans, and Asian children (3:1 ratio in all races compared with whites).

Sex

Neonatal lupus erythematosus of the heart affects girls more often than boys (female-to-male ratio of 2:1). Neonatal lupus erythematosus of the skin affects girls more often than boys (female-to-male ratio of 3:1). Prepubertal female-to-male ratios have been reported to be between 1:1 and 3:1, whereas the ratio in postpubertal children is between 8:1 and 10:1.

Age

Neonatal lupus erythematosus affects children aged 0-6 months, whereas lupus erythematosus of childhood affects prepubertal and postpubertal children.

Clinical

History

• Neonatal lupus erythematosus
  • The mother usually discovers neonatal lupus erythematosus (NLE) that affects the skin shortly after birth. In some instances, the mother notes that the infant is sensitive to sunlight.
  • Neonatal lupus erythematosus that affects the heart is usually noted upon physical examination at birth but may be recognized with ultrasonography in utero.
  • Mothers may be asymptomatic or have symptoms of lupus erythematosus (LE) or Sjögren syndrome. When carefully questioned, they may report dry eyes, arthralgia, myalgia, or arthritis. A recent report linked the presence of hypothyroidism in mothers with Ro with an increased risk of CHB.
• Lupus erythematosus of childhood
  • Photosensitivity, arthritis, arthralgia, and fever may be the presenting symptoms. The patient may also report having a rash.
  • Adults with discoid lupus erythematosus (DLE) lesions have a low risk of systemic disease; however, risk of systemic disease and progression to systemic involvement appears to be greater in children, with one report suggesting rates of 50%. Therefore, question children with discoid lupus erythematosus or subacute cutaneous lupus erythematosus (SCLE) lesions about symptoms of pleuritis, pericarditis, and neurologic or renal involvement.

Physical

• Cutaneous findings in neonatal lupus erythematosus
  • Annular erythematous plaques with a slight scale characterize neonatal lupus erythematosus. Atrophic lesions may develop; however, over time, even these lesions leave little residual change. These lesions are usually not present at birth but may become evident shortly afterward, particularly in infants exposed to light therapy.
  • Telangiectasia is often prominent and is the sole cutaneous manifestation reported in some patients.
  • Dyspigmentation is frequent, but, with time, this change spontaneously resolves.
  • Cutaneous lesions usually resolve. They are present at birth or shortly after and rarely appear when the infant is older than 6 months. The head and neck are the most commonly affected areas, but lesions may also appear on the arms and trunk.
• Cardiac disease of neonatal lupus erythematosus
  • Complete CHB is the usual finding, but incomplete heart block is possible. This finding may be noted as a bradycardia in utero or during physical examination at birth.
  • Heart failure is a well-recognized complication during the neonatal period. Recently, incomplete heart block, as well as prolongation of the QT interval, has been noted.
• Other manifestations of neonatal lupus erythematosus
  • Hepatosplenomegaly is an occasional transient finding. Transaminase elevation is often present.
  • Pneumonitis may manifest as tachypnea or tachycardia.
  • Thrombocytopenia may manifest as petechiae.
• Findings in childhood lupus erythematosus: Lupus erythematosus in children may manifest as a polyarthritis, discoid lupus erythematosus or subacute cutaneous lupus erythematosus lesions, malar rash of lupus erythematosus, or photosensitive dermatitis.
• Drug-induced lupus erythematosus
  • Drug-induced lupus erythematosus may develop in children and adolescents.
  • Recently, multiple cases of a lupus erythematosus–like disease have been reported in patients who are taking minocycline for acne. These patients often demonstrate fever and polyarthralgia or arthritis.
  • Recently, incomplete heart block, as well as prolongation of the QT interval, has been noted.

Causes

• Neonatal lupus erythematosus is related to the transplacental passage of autoantibodies.
• The cause of lupus erythematosus in children and adolescents is unknown, but genetic predisposition is likely.
• Drugs, in particular minocycline, may be responsible for drug-induced disease.

Differential Diagnoses

Other Problems to Be Considered

Juvenile dermatomyositis
Juvenile sarcoidosis
Drug eruptions
Viral or bacterial infections
Malignancy
Toxic exposures
Primary immunodeficiencies

Workup

Laboratory Studies

• Neonatal lupus erythematosus (NLE) is related to the anti-Ro (SS-A) antibody in more than 90% of patients. Occasionally, patients only have anti-La (SS-B) or anti-U1RNP antibodies.
• Test patients with neonatal lupus erythematosus for cytopenia (CBC count) and liver enzyme elevations.
• Children in whom systemic lupus erythematosus (SLE) is suspected should undergo a serologic evaluation, including antinuclear antibody (ANA), anti-dsDNA, anti-Sm, anti-RNP, anti-Ro (SS-A), and anti-La (SS-B), as well as measurement of complement levels. Also test for other organ involvement, including a CBC count and tests of renal function.

Other Tests

• Electrocardiography reveals the degree of heart block in a patient in whom neonatal lupus erythematosus is suspected.

Procedures

• Skin biopsy is useful in patients with either neonatal lupus erythematosus or cutaneous lesions of lupus erythematosus during childhood.

Histologic Findings

• Skin biopsy findings reveal interface dermatitis.
• Epidermal atrophy may be found.
• Inflammatory infiltrate may be so intense that bulla formation may develop histologically.

Treatment

Medical Care

• Neonatal lupus erythematosus (NLE) that affects the skin, blood, spleen, or liver is usually self-limited and resolves without intervention within 2-6 months.
• In severe cases, neonatal lupus erythematosus that affects the heart may result in cardiac failure and death. A pacemaker is often necessary. Treat skin conditions with sunscreen, topical corticosteroids, and antimalarial agents.

Surgical Care

• No specific surgical care is indicated for patients with lupus erythematosus.
• Pacemaker placement may be needed in patients with neonatal lupus erythematosus that affects the heart.

Consultations

• Dermatologist
• Rheumatologist
• Nephrologist
• Neurologist
• Immunologist
• Hematologist

Diet

• No specific diet is recommended.

Activity

• Limit activity only if the disease is active and base restrictions on the patient's abilities.
• Patients with skin disease should restrict their sun exposure.

Medication

Neonatal lupus erythematosus (NLE) does not require specific therapy. Some research suggests that infants from subsequent pregnancies are less likely to be affected by cardiac neonatal lupus erythematosus if the mother is treated with prednisolone, dexamethasone, or betamethasone.

Sunscreens are also useful in the treatment of cutaneous lupus erythematosus in children and adults. Sunscreens do not block all wavelengths of light; therefore, consider the preparation and its characteristics, rather than suggesting that any sunscreen is effective. In adult studies, the wavelengths of light responsible for induction of cutaneous lupus erythematosus are within the UV-B and UV-A range. Unfortunately, many sunscreens are labeled for UV-B protection only with the sun-protection factor (SPF). Patients and parents should be advised to apply sunscreen well before exposure and to use a sunscreen with a high SPF that provides a broad-spectrum (UV-A) coverage and is water-resistant. Reapplication after several hours is necessary. Encourage behavior modification of UV avoidance.

Topical corticosteroids

These agents are used to control cutaneous lesions. Select a specific agent based on treatment site and type of lesion. Facial skin is more prone to atrophy than skin of the scalp or hands; therefore, use a weaker agent on the face. Thick lesions may require more potent agents. In addition, treat hair-bearing areas with a lotion, gel, or foam instead of cream or ointment.

Hydrocortisone (Dermacort, Westcort, CortaGel)

Lower potency topical steroids (0.5%, 1%, 2.5%) useful on face and intertriginous areas. Has mineralocorticoid and glucocorticoid effects that result in anti-inflammatory activity.

Dosing

Adult

Apply tid initially; reduce as lesions remit

Pediatric

Administer as in adults

Interactions

None reported

Contraindications

Documented hypersensitivity; viral, fungal, and bacterial skin infections

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Prolonged use, application over large surface areas, application of potent steroids, and occlusive dressings may increase systemic absorption of corticosteroids and may cause Cushing syndrome, reversible HPA axis suppression, hyperglycemia, and glycosuria

Triamcinolone acetate (Aristocort, Kenalog)

Decreases inflammation by suppressing migration of PMNs and reversing capillary permeability. Moderate-potency topical steroid available in both ointment (0.1%) and cream (0.1%, 0.5%).

Dosing

Adult

Apply tid initially; reduce as lesions remit

Pediatric

Administer as in adults

Interactions

None reported

Contraindications

Documented hypersensitivity; fungal, viral, and bacterial skin infections

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Prolonged use may cause skin atrophy or steroid acne (less of a concern in prepubertal individuals); avoid use on face and intertriginous areas; limit use to 3 wk; systemic absorption of topical corticosteroids may cause Cushing syndrome, reversible HPA axis suppression, hyperglycemia, and glycosuria

Clobetasol propionate (Temovate)

Superpotent topical steroid. Decreases inflammation by suppressing migration of PMNs and reversing capillary permeability.

Dosing

Adult

Apply tid initially; reduce as lesions remit

Pediatric

Children: Not established
Adolescents: Administer as in adults

Interactions

None reported

Contraindications

Documented hypersensitivity; viral, fungal, and bacterial skin infections

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Prolonged use may cause skin atrophy or steroid acne; avoid use on face and intertriginous areas; limit use to 3 wk and to older children and adults; systemic absorption of topical corticosteroids may cause Cushing syndrome, reversible HPA axis suppression, hyperglycemia, and glycosuria

Betamethasone dipropionate (Alphatrex, Diprolene, Maxivate)

Superpotent topical steroid. Decreases inflammation by suppressing migration of PMNs and reversing capillary permeability.

Dosing

Adult

Apply tid initially; reduce as lesions remit

Pediatric

Children: Not established
Adolescents: Administer as in adults

Interactions

None reported

Contraindications

Documented hypersensitivity; viral, fungal, and bacterial skin infections

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Prolonged use may cause skin atrophy or steroid acne; avoid use on face and intertriginous areas; limit use to 3 wk and to older children and adults; systemic absorption of topical corticosteroids may cause Cushing syndrome, reversible HPA axis suppression, hyperglycemia, and glycosuria

Immunosuppressive agents

Patients with immune dysregulation and autoimmunity often benefit from immunosuppression. These drugs are useful in patients with skin disease that is unresponsive to topical agents and in patients with arthritis that does not respond to NSAIDs. These drugs are not needed in neonatal lupus erythematosus but may be used in children with skin or joint disease of systemic lupus erythematosus.

Hydroxychloroquine (Plaquenil)

Inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions.
Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.

Dosing

Adult

200-400 mg (as sulfate salt)/d (3-7 mg/kg/d) PO

Pediatric

3-5 mg base/kg/d PO; not to exceed 7 mg (as sulfate salt)/kg/d

Interactions

Few reports; chloroquine may potentiate possible ocular toxicity of other drugs (eg, cisplatin); serum levels increase with cimetidine; magnesium trisilicate may decrease absorption

Contraindications

Documented hypersensitivity; G-6-PD deficiency; porphyria; psoriasis; retinal and visual field changes attributable to 4-aminoquinolones

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in hepatic disease, G-6-PD deficiency, psoriasis, and porphyria; not recommended for long-term use in children; perform periodic (6 mo) ophthalmologic examinations; periodically test for muscle weakness; adverse effects are infrequent and include eye changes, GI symptoms (of which diarrhea is most prominent), and CNS changes

Corticosteroids

These agents are useful in adults or children with renal, CNS, or severe hematologic disease associated with systemic lupus erythematosus. Rarely needed in neonatal lupus erythematosus but may be used in patients with severe hepatitis or thrombocytopenia.

Prednisone (Deltasone, Orasone)

May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Dosing

Adult

5-60 mg/d PO qd or divided bid/qid

Pediatric

1-2 mg/kg PO divided bid/qid

Interactions

Coadministration with estrogens may decrease prednisone clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics

Contraindications

Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, cataract formation, growth suppression, and infections may develop with glucocorticoid use

Non-steroid topical immunosuppressants

These agents may be useful in postpubertal children with cutaneous systemic lupus erythematosus. Prolonged use of topical corticosteroids may produce significant skin adnexal atrophy. If needed, may use intermittently and short-term as second-line therapy.

Pimecrolimus (Elidel)

Second-line agent for short-term and intermittent treatment unresponsive to, or intolerant of other treatments. Topical calcineurin inhibitor derived from ascomycin, a natural substance produced by the fungus Streptomyces hygroscopicus var ascomyceticus. Penetrates inflamed epidermis to inhibit T-cell activation by blocking transcription of proinflammatory cytokine genes such as interleukin-2, interferon gamma (Th1-type), interleukin-4, and interleukin-10 (Th2-type). Blocks catalytic function of calcineurin. Prevents release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/IgE. Selectively inhibits production and release of inflammatory cytokines from activated T cells by binding to cytosolic immunophilin receptor macrophilin-12. The resulting complex inhibits phosphatase calcineurin, thus blocking T-cell activation and cytokine release. Cutaneous atrophy was not observed in clinical trials, which is a potential advantage over topical corticosteroids.

Dosing

Adult

Apply topically to affected areas bid
Short-term and intermittent use only

Pediatric

<2 years: Not indicated
>2 years: Administer bid as in adults
Short-term and intermittent use only

Interactions

CYP3A inhibitors may increase pimecrolimus levels in patients in whom increased absorption expected

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Potential exacerbation of existing infection at site of application; may cause burning and irritation; caution with conditions that suppress the immune system (eg, AIDS, cancer); possible risk of lymph node or skin cancer based on animal studies and a small number of patients, cancer risk increased as amount of drug given increased; may increase risk of viral infections (tacrolimus therapy has been associated with risk of developing eczema herpeticum, varicella zoster, and herpes simplex); other adverse effects include headache, sore throat, flulike symptoms, fever, and cough

Tacrolimus (Protopic)

Second-line agent for short-term and intermittent treatment unresponsive to, or intolerant of other treatments. Topical calcineurin inhibitor - Penetrates inflamed epidermis to inhibit T-cell activation by blocking transcription of proinflammatory cytokine genes such as interleukin-2, interferon gamma (Th1-type), interleukin-4, and interleukin-10 (Th2-type). Blocks catalytic function of calcineurin. Prevents release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/IgE. Also inhibits transcription for genes that encode IL-3, IL-4, IL-5, GM-CSF, and TNF-alpha, all of which are involved in the early stages of T-cell activation. Cutaneous atrophy was not observed in clinical trials, which is a potential advantage over topical corticosteroids.

Dosing

Adult

Apply thin layer of ointment (concentrations of 0.03 and 0.1%) to affected skin areas bid and rub in gently and completely; continue treatment for 1 wk after clearing of signs and symptoms
Short-term and intermittent use only

Pediatric

<2 years: Not indicated
2-15 years: Apply lower strength (ie, 0.03%) ointment bid to affected area(s)
>15 years: Administer as in adults
Short-term and intermittent use only

Interactions

CYP3A inhibitors may increase levels in patients in whom increased absorption expected

Contraindications

Documented hypersensitivity to tacrolimus or components of ointment

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Patients may experience a burning sensation during first few days of application; skin can become photosensitive and patients should be cautioned about exposure to direct or artificial sunlight and to use sunscreen; safety and efficacy in infected atopic dermatitis is not known; application under occlusion, which may promote systemic exposure, has not been evaluated (do not use tacrolimus ointment with occlusive dressings); absorption of tacrolimus following topical applications of tacrolimus ointment is minimal (relative to systemic administration), but tacrolimus is excreted in human milk, and, thus, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account importance of drug to mother (potential for serious adverse reactions in nursing infants from tacrolimus should also be a concern); potential exacerbation of existing infection at site of application; may cause burning and irritation; caution with conditions that suppress the immune system (eg, AIDS, cancer); possible risk of lymph node or skin cancer based on animal studies and a small number of patients, cancer risk increased as amount of drug given increased; may increase risk of viral infections (tacrolimus therapy has been associated with risk of developing eczema herpeticum, varicella zoster, and herpes simplex); other adverse effects include headache, sore throat, flulike symptoms, fever, and cough

Follow-up

Further Inpatient Care

• Inpatient care is not needed for patients with skin disease.

Further Outpatient Care

• Patients with neonatal lupus erythematosus (NLE) of the skin do not require monitoring after lesions resolve. They may be more prone to develop lupus erythematosus later in life, but this reflects their genetic predisposition, not that they had neonatal lupus erythematosus. Their nonaffected siblings are also at risk for development of systemic lupus erythematosus.
• Patients with neonatal lupus erythematosus with cardiac involvement require regular monitoring to assess cardiac function and the need for a pacemaker.

Transfer

• Consider transfer to a tertiary care center for all children and neonates with lupus erythematosus.

Deterrence/Prevention

• Mothers of neonates with neonatal lupus erythematosus, particularly neonates with CHB, have a 2-fold to 3-fold increased risk of subsequent affected neonates. An estimated 25% of subsequent pregnancies are affected. Therefore, carefully monitor subsequent pregnancies, particularly at 18-24 weeks’ gestation.
• Consult an obstetrician with experience with high-risk pregnancies and consider administration of prednisolone or fluorinated steroids during subsequent pregnancies to prevent neonatal lupus erythematosus. In at least one instance, CHB was prevented with the use of corticosteroids beginning at 10 weeks’ gestation, azathioprine shortly thereafter, and plasmapheresis beginning at 18 weeks’ gestation.²

Prognosis

• Neonatal lupus erythematosus
  • Generally, skin disease is self-limited.
  • Hepatosplenomegaly is self-limited, although death due to hepatitis may occur.
  • Cytopenia is self-limited; however, if severe thrombocytopenia is present, bleeding can affect the prognosis.
  • Cardiac involvement is associated with a poor outcome in many patients, including some who receive pacemakers.

Patient Education

• Assess and educate the mother about follow-up care for a child with neonatal lupus erythematosus and the potential effects on subsequent pregnancies.
• Instruct patients about sun avoidance, use of protective clothing, and proper use of sunscreens and topical corticosteroids.
• For excellent patient education resources, visit eMedicine's Blood and Lymphatic System Center. Also, see eMedicine's patient education article Lupus (Systemic Lupus Erythematosus).
• In mothers who are asymptomatic at the time of delivery of a neonate with cutaneous neonatal lupus erythematosus or CHB, assess for the future development of lupus erythematosus or another collagen vascular disease.

Miscellaneous

Medicolegal Pitfalls

• Failure to diagnose
• Failure to recognize cardiac complications of neonatal lupus erythematosus (NLE)
• Failure to monitor subsequent pregnancies or the course of the mother

Special Concerns

• Prenatal ultrasonography may help identify neonatal lupus erythematosus that affects the heart.

Multimedia

Media file 1: This child presented with petechial lesions, hepatosplenomegaly, and thrombocytopenia. Initially he was thought to have histiocytosis (Letterer-Siwe disease); however, a skin biopsy revealed an interface dermatitis, and his mother had circulating autoantibodies.

Media file 2: This child was one fraternal twin. Her sibling was not affected, although the mother and both infants had similar autoantibodies in their circulation. Eventually, the lesions resolved and healed without sequelae.

Media file 3: Neonatal lupus erythematosus.

References

1. Boutjdir M, Chen L, Zhang ZH, et al. Serum and immunoglobulin G from the mother of a child with congenital heart block induce conduction abnormalities and inhibit L-type calcium channels in a rat heart model. Pediatr Res. Jul 1998;44(1):11-9. [Medline].

2. Shinohara K, Miyagawa S, Fujita T, et al. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol. Jun 1999;93(6):952-7. [Medline].

3. Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol. Sep 1999;11(5):384-92. [Medline].

4. Austin-Ward E, Castillo S, Cuchacovich M, et al. Neonatal lupus syndrome: a case with chondrodysplasia punctata and other unusual manifestations. J Med Genet. Aug 1998;35(8):695-7. [Medline].

5. Brucato A, Franceschini F, Buyon JP. Neonatal lupus: long-term outcomes of mothers and children and recurrence rate. Clin Exp Rheumatol. Sep-Oct 1997;15(5):467-73. [Medline].

6. Buyon JP. The heart and skin of neonatal lupus: does maternal health matter? [comment] [editorial]. Am J Med. Jun 15 2000;108(9):741-3. [Medline].

7. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. Jun 1998;31(7):1658-66. [Medline].

8. Callen JP, Fowler JF, Kulick KB, et al. Neonatal lupus erythematosus occurring in one fraternal twin. Serologic and immunogenetic studies. Arthritis Rheum. Mar 1985;28(3):271-5. [Medline].

9. Costedoat-Chalumeau N, Amoura Z, Villain E, et al. Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block?A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther. 2005;7(2):69-73. [Medline].

10. Fritsch C, Hoebeke J, Dali H, et al. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther. Nov 4 2005;8(1):R4. [Medline].

11. Jones EM, Callen JP. Collagen vascular diseases of childhood. Pediatr Clin North Am. Aug 1991;38(4):1019-39. [Medline].

12. Krafchik BR. Neonatal lupus erythematosus. Adv Exp Med Biol. 1999;455:23-6. [Medline].

13. Lawrence S, Luy L, Laxer R, et al. The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block [see comments]. Am J Med. Jun 15 2000;108(9):705-9. [Medline].

14. Lee LA. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev. Apr 2005;4(4):207-13. [Medline].

15. Lee LA, Weston WL. Cutaneous lupus erythematosus during the neonatal and childhood periods. Lupus. 1997;6(2):132-8. [Medline].

16. Lee LA, Weston WL. Special considerations concerning the cutaneous manifestations of rheumatic disease in children. Cutaneous Manifestations of Rheumatic Diseases. 1995;323-7.

17. [Guideline] Lehman TJ. A practical guide to systemic lupus erythematosus. Pediatr Clin North Am. Oct 1995;42(5):1223-38. [Medline].

18. Lin SC, Shyur SD, Huang LH, et al. Neonatal lupus erythematosus with cholestatic hepatitis. J Microbiol Immunol Infect. Apr 2004;37(2):131-4. [Medline].

19. Manthorpe R, Svensson A, Wirestrand LE. Late neonatal lupus erythematosus onset in a child born of a mother with primary Sjogren's syndrome. Ann Rheum Dis. Nov 2004;63(11):1496-7. [Medline].

20. Miranda ME, Tseng CE, Rashbaum W, et al. Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol. Nov 1 1998;161(9):5061-9. [Medline].

21. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. Nov 1999;42(11):2335-45. [Medline].

22. Sandborg CI. Childhood systemic lupus erythematosus and neonatal lupus syndrome. Curr Opin Rheumatol. Sep 1998;10(5):481-7. [Medline].

23. Scheker LE, Kasteler JS, Callen JP. Neonatal lupus erythematosus mimicking langerhans cell histiocytosis. Pediatr Dermatol. Mar-Apr 2003;20(2):164-6. [Medline].

24. See Y, Koh ET, Boey ML. One hundred and seventy cases of childhood-onset rheumatological disease in Singapore. Ann Acad Med Singapore. Jul 1998;27(4):496-502. [Medline].

25. Silverman ED, Laxer RM. Neonatal lupus erythematosus. Rheum Dis Clin North Am. Aug 1997;23(3):599-618. [Medline].

26. Solomon BA, Laude TA, Shalita AR. Neonatal lupus erythematosus: discordant disease expression of U1RNP- positive antibodies in fraternal twins--is this a subset of neonatal lupus erythematosus or a new distinct syndrome?. J Am Acad Dermatol. May 1995;32(5 Pt 2):858-62. [Medline].

27. Spence D, Hornberger L, Hamilton R, Silverman ED. Increased Risk of Complete Congenital Heart Block in Infants Born to Women with Hypothyroidism and Anti-Ro and/or Anti-La Antibodies. J Rheumatol. Jan 2006;33(1):167-70. [Medline].

28. Thornton CM, Eichenfield LF, Shinall EA, et al. Cutaneous telangiectases in neonatal lupus erythematosus. J Am Acad Dermatol. Jul 1995;33(1):19-25. [Medline].

29. Wananukul S, Watana D, Pongprasit P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol. Sep-Oct 1998;15(5):342-6. [Medline].

30. Weston WL, Morelli JG, Lee LA. The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus. J Am Acad Dermatol. May 1999;40(5 Pt 1):675-81. [Medline].

31. Yang CH, Chen JY, Lee SC, Luo SF. Successful preventive treatment of congenital heart block during pregnancy in a woman with systemic lupus erythematosus and anti-Sjogren's syndrome A/Ro antibody. J Microbiol Immunol Infect. 38(5):365-9. [Medline].

32. Yukiko N. Immune responses to SS-A 52-kDa and 60-kDa proteins and to SS-B 50-kDa protein in mothers of infants with neonatal lupus erythematosus. Br J Dermatol. May 2000;142(5):908-12. [Medline].

Keywords

neonatal lupus, cutaneous lupus erythematosus, lupus erythematosus of childhood, neonatal lupus erythematosus, LE, NLE, cutaneous lesions, SCLE, subacute cutaneous lupus erythematosus, discoid lupus erythematosus, DLE, congenital heart block, CHB, telangiectasia, dyspigmentation, atrophic lesions, syncope, heart failure, Sjögren syndrome, arthritis, arthralgia, hepatosplenomegaly, pneumonitis, drug-induced lupus erythematosus, prolonged QT interval

Contributor Information and Disclosures

Author

Jeffrey P Callen, MD, Professor of Medicine, Chief, Division of Dermatology, University of Louisville School of Medicine
Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology
Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Honoraria Consulting; Centocor Honoraria Consulting; Genetech Honoraria Consulting; Celgene Honoraria Consulting

Medical Editor

Barry L Myones, MD, Associate Professor, Departments of Pediatrics and Immunology, Pediatric Rheumatology Section, Baylor College of Medicine; Director of Research, Pediatric Rheumatology Center, Texas Children's Hospital
Barry L Myones, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American College of Rheumatology, American Heart Association, American Society for Microbiology, Clinical Immunology Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Thomas JA Lehman, MD, FAAP, FACR, Clinical Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Rheumatology, Weill-Cornell University; Chief, Hospital for Special Surgery
Thomas JA Lehman, MD, FAAP, FACR is a member of the following medical societies: PM American Allergy Society
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting

Chief Editor

Lawrence K Jung, MD, Chief, Division of Pediatric Rheumatology, Children's National Medical Center
Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, and New York Academy of Sciences
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)